New Targets for A1C and Blood Pressure Control: One Size Does Not Fit All

Ann Bullock, MD
Division of Diabetes Treatment and Prevention
Indian Health Service
This presentation:

- Give an overview of the evolution in the evidence for glucose and blood pressure targets in type 2 diabetes
- Current status of glucose and blood pressure targets: one size doesn’t fit all
- Clinical practice guidelines vs. performance measures
- What all this means for clinical practice
Remember when we thought that the same diabetes targets applied to everyone?

- A1C <7%
- BP <130/80 mmHg
- LDL <100mg/dL

That is so 2007!

Universal targets sure are easier for data people
But they don’t work well for many of our patients
“First, do no harm”
Glucose targets across the lifespan

“To everything there is a season…”
United Kingdom Prospective Diabetes Study (UKPDS)

Years

A1C (%)

Conventional Group

Intensive Group

UKPDS Group Lancet 1998;352:837–53
UKPDS: Post-Trial Changes in A1C

## UKPDS: “Legacy Effect” of Glucose Therapy

*After median 8.8 years post-trial follow-up*

<table>
<thead>
<tr>
<th>Aggregate Endpoint</th>
<th>1997</th>
<th>2007</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any diabetes related endpoint</td>
<td><strong>RRR:</strong> 12%</td>
<td>9%</td>
</tr>
<tr>
<td></td>
<td><strong>P:</strong> 0.029</td>
<td>0.040</td>
</tr>
<tr>
<td>Microvascular disease</td>
<td><strong>RRR:</strong> 25%</td>
<td>24%</td>
</tr>
<tr>
<td></td>
<td><strong>P:</strong> 0.009</td>
<td>0.001</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td><strong>RRR:</strong> 16%</td>
<td>15%</td>
</tr>
<tr>
<td></td>
<td><strong>P:</strong> 0.052</td>
<td>0.014</td>
</tr>
<tr>
<td>All-cause mortality</td>
<td><strong>RRR:</strong> 6%</td>
<td>13%</td>
</tr>
<tr>
<td></td>
<td><strong>P:</strong> 0.44</td>
<td>0.007</td>
</tr>
</tbody>
</table>

**RRR** = Relative Risk Reduction       **P** = Log Rank

“The UKPDS showed the benefits of an intensive strategy to control blood glucose levels in patients with type 2 diabetes sustained up to 10 yrs after cessation of the randomized intervention. Benefits persisted despite the early loss of within-trial differences in A1C levels between the intensive-therapy group and conventional-therapy group – a so-called legacy effect.”

UKPDS

- Showed that glycemic control early in diabetes has lasting benefit, including for CVD risk

- However, it was interpreted as implying that everyone should have an A1C <7%--and national guidelines followed suit

  - But UKPDS included only healthy, newly-diagnosed patients <65 yrs old

Lancet 1998;352:837-853
And then came major studies on intensive glucose control in more “real world” diabetes populations

- ACCORD, ADVANCE, and VADT
  \( \text{NEJM 2008;358:245-259 and 2560-72, NEJM 2009;360:129-139} \)

- Showed little benefit to intensive glucose control other than for nephropathy (in ACCORD and ADVANCE)

- And showed increased mortality (ACCORD), weight gain, and hypoglycemia
**Impact of Intensive Therapy for Diabetes: Summary of Major Clinical Trials**

<table>
<thead>
<tr>
<th>Study</th>
<th>Microvasc</th>
<th>CVD</th>
<th>Mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>UKPDS</td>
<td>▼</td>
<td>▼</td>
<td>▼</td>
</tr>
<tr>
<td>DCCT / EDIC*</td>
<td>▼</td>
<td>▼</td>
<td>▼</td>
</tr>
<tr>
<td>ACCORD</td>
<td>▼</td>
<td>▼</td>
<td>▼</td>
</tr>
<tr>
<td>ADVANCE</td>
<td>▼</td>
<td>▼</td>
<td>▼</td>
</tr>
<tr>
<td>VADT</td>
<td>▼</td>
<td>▼</td>
<td>▼</td>
</tr>
</tbody>
</table>

Kendall DM, Bergenstal RM. © International Diabetes Center 2009

2009 ADA Statement on Glucose Control and CVD Prevention

- May not affect CVD outcomes after macrovascular disease established—but good glucose control in the early years of DM may affect long-term risk of macrovascular disease
- Makes a difference in microvascular disease
- However, BG goal should be adjusted to the individual patient
  - In general, A1C goal: <7%
    - Lower goal if short duration DM, long life expectancy, and little co-morbidity
    - Higher goal if the converse—there are risks with aggressive control

And the discussion has continued

- Meta-analysis of 13 recent RCTs (>34,000 pts) that evaluated intensive glucose lowering:
  - *Limited* benefits on all-cause and CV mortality
  - At best, *modest* benefits for microvascular disease
    - ↓ albuminuria, a *trend* toward ↓retinopathy, but little else
  - Severe hypoglycemic events doubled  *BMJ* 2011;343:d4243 doi:10.1136/bmj.d4243

- *Guidelines* starting to reflect recent evidence, now Performance *Measures* are being re-thought
  - *Much more benefit* to ↓ patient’s A1C from 9% to 7.1% than to ↓ it from 7.1% to 6.9%
  - Unknown effects of adding on multiple meds to achieve target  *Diabetes Care* 2011;34:1651-1659
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach

Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
3. ANTI-HYPERGLYCEMIC THERAPY

- **Glycemic targets**
  - $\text{HbA1c} < 7.0\%$ (mean $\text{PG} \sim 150\text{-}160 \text{mg/dl} \ [8.3\text{-}8.9 \text{mmol/l}])$
  - Pre-prandial $\text{PG} < 130 \text{mg/dl} \ (7.2 \text{mmol/l})$
  - Post-prandial $\text{PG} < 180 \text{mg/dl} \ (10.0 \text{mmol/l})$
  - **Individualization** is key:
    - Tighter targets (6.0 - 6.5%) - younger, healthier
    - Looser targets (7.5 - 8.0%+) - older, comorbidities, hypoglycemia prone, etc.
  - Avoidance of hypoglycemia

PG = plasma glucose

*Diabetes Care, Diabetologia. 19 April 2012 [Epub ahead of print]*
Approach to management of hyperglycemia:

- Patient attitude and expected treatment efforts:
  - more stringent: highly motivated, adherent, excellent self-care capacities
  - less stringent: less motivated, non-adherent, poor self-care capacities

- Risks potentially associated with hypoglycemia, other adverse events:
  - low
  - high

- Disease duration:
  - newly diagnosed
  - long-standing

- Life expectancy:
  - long
  - short

- Important comorbidities:
  - absent
  - few / mild
  - severe

- Established vascular complications:
  - absent
  - few / mild
  - severe

- Resources, support system:
  - readily available
  - limited

Figure 1

Diabetes Care, Diabetologia. 19 April 2012 [Epub ahead of print]
A1c Variability “Speedometer”

Lab Report Says:
7.4%
7.2
7.0
6.9
error=3%

error=7%
### VA uses A1C target ranges

<table>
<thead>
<tr>
<th>Major comorbidity or physiologic age</th>
<th>Microvascular complications</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Absent or mild</td>
</tr>
<tr>
<td>Absent &gt; 10 years of life expectancy</td>
<td>&lt; 7</td>
</tr>
<tr>
<td>Present 5-10 years of life expectancy</td>
<td>&lt; 8</td>
</tr>
<tr>
<td>Marked &lt; 5 years of life expectancy</td>
<td>8-9</td>
</tr>
</tbody>
</table>
American Geriatrics Society
Five Things Physicians and Patients Should Question

#3: Avoid using medications to achieve hemoglobin A1c <7.5% in most adults age 65 and older; moderate control is generally better.

There is no evidence that using medications to achieve tight glycemic control in older adults with type 2 diabetes is beneficial. Among non-older adults, except for long-term reductions in myocardial infarction and mortality with metformin, using medications to achieve glycated hemoglobin levels less than 7% is associated with harms, including higher mortality rates. Tight control has been consistently shown to produce higher rates of hypoglycemia in older adults. Given the long timeframe to achieve theorized microvascular benefits of tight control, glycemic targets should reflect patient goals, health status, and life expectancy. Reasonable glycemic targets would be 7.0 – 7.5% in healthy older adults with long life expectancy, 7.5 – 8.0% in those with moderate comorbidity and a life expectancy < 10 years, and 8.0 – 9.0% in those with multiple morbidities and shorter life expectancy.

“Choosing Wisely”, ABIM Foundation, 2013
“Wait a minute—what happened to all the hype about getting everyone’s A1C down to <7% or even lower??”

- Do people who have A1Cs <7%, on their own or with a little bit of medication, do better in the long-run? Yes!
  - But this is a marker of their overall systemic health

- That is not the same thing as having to use 3 or 4 meds to beat someone’s glucoses down to achieve a low target
  - Not known if polypharmacy is safe, effective or cost-effective
  - Hypoglycemia risk increases

- Performance measures (like GPRA) have reflected the national guidelines—and providers felt pressured to get all their patients’ A1Cs down to <7%, no matter what it took
  - GPRA has already changed for 2013!
So, what do we do with all this?

- **Individualize** glucose targets—really!
  - Younger, healthier patients: aim for <7% (or lower)
    - Excellent glucose control achieved and maintained early in the course of diabetes has long-term benefits, including for CVD
  - Longer duration of diabetes, more co-morbidities and lots of meds already: liberalize glucose targets (ranges)
    - Think carefully about whether to add another medication (and which one) to lower glucose
    - Hypoglycemia causes “considerable morbidity and even mortality”

- Focus some efforts on patients whose A1Cs >9.5%
- Future EHRs: help with selecting, documenting target for each patient—VA already has a prototype
Absolute number of events prevented by different interventions per 1000 patient years of treatment (data taken from Cholesterol Treatment Trialists’ Collaboration and Blood Pressure Lowering Treatment Trialists’ Collaboration).

- Per 4 mm Hg lower systolic blood pressure
- Per 1 mmol/L lower low density lipoprotein-cholesterol
- Per 0.9% lower glycated haemoglobin

Preiss D, Ray K K BMJ 2011;343:bmj.d4243
Blood Pressure

A Similar Story
Blood Pressure Target

- As with glucose targets, UKPDS played a major role in target selection for BP in international guidelines.

- For diastolic BP target, so did the randomized Hypertension Optimal Treatment (HOT) study.
  - Study paper noted ↓ CV risk in diabetic patients with DBP <80 mm Hg.
  - Accompanying editorial noted slight ↑ mortality in intensively treated diabetic patients with ischemic heart disease so recommended caution in lowering BP to <140/85 in this group. 

UKPDS

• “This paper reports that patients with hypertension and type 2 diabetes assigned to tight control of blood pressure achieved a significant reduction in risk of 24% for any end points related to diabetes, 32% for death related to diabetes, 44% for stroke, and 37% for microvascular disease. In addition there was a 56% reduction in risk of heart failure. The mean blood pressure over nine years was 144/82mm Hg on tight control compared with a less tight control mean of 154/87mm Hg”

  BMJ 1998;317(7160):703-713

• UKPDS observational study showed that “risk of diabetic complications was strongly associated with raised blood pressure. Any reduction in blood pressure is likely to reduce the risk of complications, with the lowest risk being in those with systolic blood pressure less than 120 mm Hg.”

  BMJ 2000;321(7258):412-419
Blood Pressure Target: JNC 7

- 2003: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)
  - Cited studies including UKPDS, HOT
  - Agreed with ADA in recommending that pts with DM have a BP goal ≤130/80
  - But noted that “available data are somewhat sparse to justify the low target level of 130/80”

_Hypertension_ 2003;42:1206-52
“Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus”

Study Overview

• In a randomized trial, 4733 patients with type 2 diabetes mellitus who were at high risk for cardiovascular events received treatment aimed at a target systolic blood pressure of less than 120 mm Hg or less than 140 mm Hg.

• At a mean follow-up of 4.7 years, the rates of the primary end point (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) were not significantly different between the two trial groups.

The ACCORD Study Group

N Engl J Med
Volume 362(17):1575-1585
April 29, 2010
“In patients with type 2 diabetes at high risk for cardiovascular events, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, did not reduce the rate of a composite outcome of fatal and nonfatal major cardiovascular events.”

“Serious adverse events attributed to antihypertensive treatment occurred in 77 of the 2362 participants in the intensive-therapy group (3.3%) and 30 of the 2372 participants in the standard-therapy group (1/3%) (P<0.001).”

Accompanying editorial: “…now we learn from the completed ACCORD study that flexible goals should probably be applied to the control of hyperglycemia, blood pressure, and dyslipidemia in patients with type 2 diabetes, taking into account individual clinical factors of importance.”

*NEJM* 2010;362:1628-1629
International Verapamil SR-Trandolapril Study (INVEST)

- Observational subgroup analysis of 6400 participants: ≥50 yrs old w/DM and CAD
  - Tight control: able to maintain SBP <130 mm Hg
  - Usual control: 130 to <140
  - Uncontrolled: ≥140

- Conclusion: “Tight control of systolic BP among patients with diabetes and CAD was not associated with improved cardiovascular outcomes compared with usual control.”

*JAMA* 2010;304:61-68
Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET)

- 25,584 pts (9,603 diabetic) >55 yrs old w/↑ CVD risk
  - Randomized to ramipril +/- telmasartan
  - Observed for 4.6 yrs
  - Primary outcome: composite of CV death, nonfatal MI or stroke, hospitalized heart failure

- The higher the initial SBP, the more benefit to lowering BP
  - For initial SBPs 130-142, benefit of lowering is primarily for stroke
  - Initial SBP around or <130, anti hypertensive treatment should be implemented with caution because of possible cardiac effects

"Our study provides evidence that in high-CV-risk patients a BP reduction to <140/90 mm Hg is associated with CV protection. Overall CV protection, however, may not be improved by lower BP targets, as recommended for higher-risk subjects in current guidelines."

J Am Coll Cardiol 2012;59:74-83

Circulation 2011;124:1727-1736
HTN and Progression of CKD to End Stage Renal Disease (ESRD)

- Associations of SBP and DBP with risk of progressing to ESRD in the Kidney Early Evaluation Program (KEEP)
  - Large, diverse community-based sample
- High SBP accounted for most of the risk for progression to ESRD
  - Highest risk in those with SBP ≥150 mm Hg
  - Risk started at SBP of 140 rather than at 130

*Arch Intern Med* 2012;172:41-47
Current BP Targets in Diabetes

- Numerous studies since ACCORD have shown that risk for CVD, CKD starts at SBP of 140 mmHg (not 130 mmHg)

- ADA 2013

  - “People with diabetes and hypertension should be treated to a systolic blood pressure goal of \(<140\) mmHg.”
    - “Lower systolic targets, such as \(<130\) mmHg, may be appropriate for certain individuals, such as younger patients, if it can be achieved without undue treatment burden.”
  
  - “Patients with diabetes should be treated to a DBP <80 mm Hg.”

- VA/DoD Goal in their 2010 Guidelines: \(<140/80\)
Going Forward

- JNC 8 will hopefully weigh in on BP targets in Diabetes
  - DBP <80 or <90?
  - Higher SBP target in elderly?
  - Any change in order of use of BP med classes?

- Target selection should be individualized
  - <140 will work well for most patients
    - Good BP control definitely reduces CVD, CKD risks
  - Balance need for good BP control with risk of problems
    - Hypotension, fatigue, polypharmacy issues are common
    - Use caution in setting even <140 target in patients who have symptoms at that SBP and/or with meds needed to achieve it
      - Higher risk: Older, comorbidities, longer duration of DM, on lots of meds, autonomic neuropathy
Clinical Practice Guidelines and Performance Measures

- **Clinical practice guidelines** help clinicians take care of individual patients; have implications for population health
  - e.g. ADA, IHS Diabetes Standards of Care

- **Performance measures** evaluate the care given to groups/populations of patients—used for accountability
  - e.g. GPRA

- For years, clinical guidelines and GPRA targets for A1C and BP have been the same #’s (A1C <7%, BP <130/80)
  - Was thought that “one size fit all”
  - Has led to confusion about difference between clinical & performance targets
The Way Forward: Clinical Action Measures as an Interim Step

BP Criteria Are Met:  

- BP < 140/90; or
- BP < 150/65; or
- SBP < 150 and on ≥ 3 mod dose BP medications

There is appropriate clinical action within 90 days:

- Increase in BP medication dose; or
- Start new BP medication; or
- Repeat BP < 140/90
So what about IHS GPRA 2013?

- How to pick a performance measure when patients should have different targets?
  - Target should cover most patients and minimize overtreatment/harm
  - The need to individualize highlights difference between them
    - A1C Target: Individualize 6-8.5+% vs GPRA <8%
    - BP Target: Individualize <140+/80-90+ vs GPRA <140/90
- **GPRA performance measures are not clinical practice guidelines**
  - Need to do what’s right for each patient
    - Some patients would benefit from lower A1C targets
    - And both these GPRA targets will still be too stringent for our older patients and those with multiple comorbidities
Diabetes Audit 2013

- Audit
  - New CVD question
  - Removed ECG question

- Audit reports
  - Removed adjectives ("ideal", "good") for A1C, BP
  - eGFR instead of creatinine
  - Targeted CVD risk factor reduction
    - Antiplatelet agent, statin
Thank You!

Questions, comments?

IHS Division of Diabetes website:
www.diabetes.ihs.gov

ann.bullock@ihs.gov